Erin Hanauer, PA
Medical · Petaluma, CANPI 1851490718
Payments from drug & device makers
Across 33 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$182
- Novartis$128
- Lilly USA, LLC$115
- Mimedx Group, Inc.$81
- Regeneron Healthcare Solutions, Inc.$57
- Arcutis Biotherapeutics, Inc.$53
- plus $192 from 6 others
What the payments were for
- Food & beverage$72790%
- Education$8010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $182 |
| Novartis | 6 | $128 |
| Lilly USA, LLC | 5 | $115 |
| Mimedx Group, Inc. | 3 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Arcutis Biotherapeutics, Inc. | 2 | $53 |
| Biofrontera Inc. | 2 | $52 |
| AbbVie | 2 | $36 |
| Organon | 1 | $33 |
| Amgen | 2 | $30 |
| Incyte Corporation | 1 | $26 |
| Galderma Laboratories, L.p. | 1 | $16 |
How this compares
$807 in reported general payments places this provider in the 60th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $222,588 |
| Clobetasol Propionate | 128 | $6,746 |
| Fluorouracil | 42 | $3,758 |
| Doxycycline Hyclate | 12 | $3,539 |
| Triamcinolone Acetonide | 201 | $2,784 |
| Tretinoin | 39 | $2,761 |
| Metronidazole | 63 | $2,545 |
| Azelaic Acid | 29 | $2,390 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 84 | $2,094 |
| Clindamycin Phosphate | 32 | $2,070 |
| Ketoconazole | 130 | $1,761 |
| Fluocinonide | 29 | $1,452 |
| Ciclopirox | 38 | $1,391 |
| Econazole Nitrate | 13 | $957 |
| Desonide | 21 | $917 |
Paid to pharmacies, not to this prescriber.
Other medical in Petaluma
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.